Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.31 |
| ▸ | DUT | P33316 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | FLT4 | P35916 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.30 |
| ▸ | TEK | Q02763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4025619 | 0.88 | — | — | |
| SCHEMBL20746386 | 0.83 | — | — | |
| SCHEMBL7605831 | 0.83 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL16203617 | 0.81 | ACHE (0.35) | DGAT1 | |
| SCHEMBL3939670 | 0.81 | TBXAS1 (0.34) | DGAT1PDE10A | |
| SCHEMBL24828571 | 0.81 | — | — | |
| SCHEMBL27943069 | 0.80 | MCL1 (0.33) | DGAT1 | |
| SCHEMBL9638271 | 0.79 | DGAT1 (0.41) | DGAT1PDE10ADUTEGFRIGF1R | |
| SCHEMBL1488779 | 0.78 | KMT2A (0.43) | DGAT1 | |
| Hydrochloric Acid SCHEMBL15455783 | 0.76 | DGAT1 (0.37) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144093-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. | 2025-05-08 | — | — | US | disclosed |
| CN-119431394-A | Pyridazinone derivatives and medical application thereof | 杭州百新生物医药科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-12133853-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| WO-2024220626-A1 | SMALL MOLECULE MODULATORS OF OGG1 | AZKARRA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| EP-4376840-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | Nura Bio, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-118043046-A | Substituted pyridine derivatives as SARM1 inhibitors | 努拉生物公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-112979654-B | Heteroaryl fused ring compounds, preparation method and application thereof | 赛诺哈勃药业（成都）有限公司 | 2024-03-19 | — | — | CN | disclosed |
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | University of Florida Research Foundation, Incorporation (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | University of Florida Research Foundation, Incorporation (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | University of Florida Research Foundation, Incorporation (US) | 2024-02-29 | — | — | US | disclosed |
| US-6255305-B1 | PSYCHOLOGICAL DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 2001-07-03 | — | — | US | disclosed |
| US-6063789-A | Aminoisoquinolines and aminotheinopyridine derivatives and their use as anti-inflammatory agents | ASTRA PHARMACEUTICALS, LTD. (GB) | 2000-05-16 | — | — | US | disclosed |
| US-6011029-A | BENZODIAZEPINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-01-04 | — | — | US | disclosed |
| EP-0892797-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-01-27 | — | — | EP | disclosed |
| EP-0892784-A1 | AMINOISOQUINOLINES AND AMINOTHIENOPYRIDINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Astra Pharmaceuticals Limited (GB) | 1999-01-27 | — | — | EP | disclosed |
| US-5710153-A | INTERLEUKIN CONVERTING ENZYME INHIBITORS | ONO PHRAMACEUTICAL CO., LTD. (JP) | 1998-01-20 | — | — | US | disclosed |
| WO-1997038977-A1 | AMINOISOQUINOLINES AND AMINOTHIENOPYRIDINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | ASTRA PHARMACEUTICALS LTD. (GB) | 1997-10-23 | — | — | WO | disclosed |
| WO-1997030992-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-08-28 | — | — | WO | disclosed |
| EP-0761680-A2 | Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-03-12 | — | — | EP | disclosed |
| US-5270334-A | 4-methoxy-5-methyl-pyran-3-ol natural products and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1993-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | FUS, SNRPE, RRBP1 | DGAT1 2833/4885PDE10A 4170/4885DUT 3195/4885 |
| US-12133853-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | DGAT1 3106/4885PDE10A 1702/4885DUT 3219/4885 |
| US-20250144093-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PDK1, PDK2, PDK3 | DGAT1 3106/4885PDE10A 1702/4885DUT 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.